help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaspan, J. B.
Right arrow Articles by Bryer-Ash, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaspan, J. B.
Right arrow Articles by Bryer-Ash, M.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 2271-2279, Copyright © 1996 by Endocrine Society

ARTICLES

The interaction of a type A retroviral particle and class II human leukocyte antigen susceptibility genes in the pathogenesis of Graves' disease

JB Jaspan, K Sullivan, RF Garry, M Lopez, M Wolfe, S Clejan, C Yan, S Tenenbaum, DM Sander, B Ahmed and M Bryer-Ash
Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.

We have previously reported that over 85% of patients with Graves' disease have detectable serum antibodies against a human intracisternal type A retroviral particle (HIAP), which are not present in age- and gender-matched controls, suggesting a role for HIAP in triggering the autoimmune process leading to Graves' disease. To investigate the interaction of this viral particle with genetic factors, 35 members of 3 kindreds, selected because of a high family prevalence of Graves' disease (a total of 11 members affected), were examined for clinical signs of thyroid dysfunction, goiter, and opthalmopathy. Thyroid function tests and autoimmune serological profiles were also obtained. In addition, subjects were tested for the presence of antibodies against HIAP by means of immunoblot analysis of their sera, and their human leukocyte antigen (HLA) class II alleles were determined by DNA methodology. Molecular genetic analyses enabled the detection of postulated HLA susceptibility haplotypes in each family. These families had 8, 4, and 5 members, respectively, with such apparent susceptibility genes and 11, 5, and 9 members, respectively, with immunological evidence of retroviral exposure. In the presence of both factors (codetected in a total of 15 members of the 3 kindreds), the incidence of Graves' disease was 100%, 67%, and 80%, respectively. One additional member of family B and 3 in family C with both viral and genetic susceptibility factors were found to have serological abnormalities and/or goiter and ocular signs consistent with evolving or preclinical Graves' disease. In families A and C, tight linkage between HLA haplotypes and Graves' disease was demonstrated in a manner consistent with recessive inheritance. The association between the occurrence of both anti-HIAP-I antibody positivity and HLA susceptibility and the presence of Graves' disease was highly significant (P < 0.001). The pathogenesis of Graves' disease in these families appears to be attributable to the interaction between the immune response to an intracisternal type A retroviral particle and immunogenetic susceptibility, leading to the autoimmune processes that underlie Graves' disease, with subsequent development of the characteristic features of the illness. Data from these families suggest that both of these factors are necessary for final disease expression. These results imply that serological evidence of retroviral exposure together with genetic HLA susceptibility are the two major predisposing factors underlying the pathogenesis of Graves' disease. Further studies will establish whether prospective identification of persons at risk for Graves' disease is possible by this means.


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
M. J. Simmonds, J. M.M. Howson, J. M. Heward, J. Carr-Smith, J. A. Franklyn, J. A. Todd, and S. C.L. Gough
A novel and major association of HLA-C in Graves' disease that eclipses the classical HLA-DRB1 effect
Hum. Mol. Genet., September 15, 2007; 16(18): 2149 - 2153.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Matsuda, M. Tomita, J.-N. Uchihara, T. Okudaira, K. Ohshiro, T. Tomoyose, T. Ikema, M. Masuda, M. Saito, M. Osame, et al.
Human T Cell Leukemia Virus Type I-Infected Patients with Hashimoto's Thyroiditis and Graves' Disease
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5704 - 5710.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. A. Mendez, K. B. DeSalvo, Y. Cao, R. F. Garry, and L. R. Espinoza
Familial erosive arthritis associated with seroreactivity to human intracisternal retroviral particle type I (HIAP-I)
Rheumatology, February 1, 2001; 40(2): 227 - 228.
[Full Text] [PDF]

Home page
 FASEB J.Home page
G. L. Wolff, R. L. Kodell, S. R. Moore, and C. A. Cooney
Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice
FASEB J, August 1, 1998; 12(11): 949 - 957.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society